SUPPLEMENT

Q3 2020 — Financial disclosures

Q3 2020PDF · 12 pages1.0 MB
Merck & Co., Inc.
Financial Highlights Package
Third Quarter 2020
Table of Contents
Table 1: 	GAAP P&L..........................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter......2
Table 2a: GAAP to Non-GAAP Reconciliation 3Q20.........................3
Table 2b: GAAP to Non-GAAP Reconciliation Sept YTD 20.............4
Table 2c: GAAP to Non-GAAP Reconciliation 3Q19.........................5
Table 2d: GAAP to Non-GAAP Reconciliation Sept YTD 19 ............6
Table 3: Sales – Current Year and Prior Year by Quarter ...............7
Table 3a: Sales – U.S. / Ex- U.S. 3Q20.............................................8
Table 3b: Sales – U.S. / Ex- U.S. Sept YTD 20 ...............................9
Table 3c: Sales – Pharmaceutical Geographic Split .......................10
Table 4: Other (Income) Expense .................................................11

-- 1 of 12 --

Sales 	12,551	$ 	12,397	$ 	1% 	35,479	$ 	34,972	$ 	1%
Costs, Expenses and Other
Cost of sales (1) 3,481 	3,990 	-13% 	9,952 	10,443 	-5%
Selling, general and administrative (1) 2,450 	2,589 	-5% 	7,383 	7,726 	-4%
Research and development (1) 3,390 	3,204 	6% 	7,721 	7,324 	5%
Restructuring costs (2) 114 	232 	-51% 	269 	444 	-39%
Other (income) expense, net (1) (312) 	35 	* 	(630) 	362 	*
Income Before Taxes 	3,428 	2,347 	46% 	10,784 	8,673 	24%
Taxes on Income (1) 483 	440 	1,611 	1,259
Net Income 	2,945 	1,907 	54% 	9,173 	7,414 	24%
Less: Net Income (Loss) Attributable to Noncontrolling Interests (1) 4 	6 	12 	(73)
Net Income Attributable to Merck & Co., Inc. 	2,941	$ 	1,901	$ 	55% 	9,161	$ 	7,487	$ 	22%
Earnings per Common Share Assuming Dilution 	1.16	$ 	0.74	$ 	57% 	3.61	$ 	2.89	$ 	25%
Average Shares Outstanding Assuming Dilution 	2,538 	2,572 	2,541 	2,587
Tax Rate (3) 14.1% 	18.7% 	14.9% 	14.5%
* 100% or greater
Sep YTD
2019
(1) Amounts include the impact of acquisition and divestiture-related costs, restructuring costs and certain other items. See accompanying tables for details.
(2) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs.
(3) The effective income tax rates for the third quarter and the first nine months of 2019 include the unfavorable impact of a charge for the acquisition of Peloton Therapeutics, Inc. for
which no tax benefit was recognized and the favorable impact of product mix. The effective income tax rate for the first nine months of 2019 reflects a net tax benefit of $360 million
related to the settlement of certain federal income tax matters.
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
GAAP
% Change
GAAP
% Change
3Q20 	3Q19 Sep YTD
2020
1	1

-- 2 of 12 --

. 	.
Sales 	12,057	$ 	10,872	$ 	12,551	$ 	35,479	$ 	10,816	$ 	11,760	$ 	12,397	$ 	34,972	$ 	11,868	$ 	46,840	$ 	1% 	1%
Costs, Expenses and Other
Cost of sales 	3,312 	3,159 	3,481 	9,952 	3,052 	3,401 	3,990 	10,443 	3,669 	14,112 	-13% 	-5%
Selling, general and administrative 	2,555 	2,378 	2,450 	7,383 	2,425 	2,712 	2,589 	7,726 	2,888 	10,615 	-5% 	-4%
Research and development 	2,209 	2,123 	3,390 	7,721 	1,931 	2,189 	3,204 	7,324 	2,548 	9,872 	6% 	5%
Restructuring costs 	72 	83 	114 	269 	153 	59 	232 	444 	194 	638 	-51% 	-39%
Other (income) expense, net 	71 	(390) 	(312) 	(630) 	188 	140 	35 	362 	(223) 	139 	* 	*
Income Before Taxes 	3,838 	3,519 	3,428 	10,784 	3,067 	3,259 	2,347 	8,673 	2,792 	11,464 	46% 	24%
Taxes on Income 	619 	509 	483 	1,611 	205 	615 	440 	1,259 	428 	1,687
Net Income 	3,219 	3,010 	2,945 	9,173 	2,862 	2,644 	1,907 	7,414 	2,364 	9,777 	54% 	24%
Less: Net Income (Loss) Attributable to Noncontrolling Interests 	- 	8 	4 	12 	(53) 	(26) 	6 	(73) 	7 	(66)
Net Income Attributable to Merck & Co., Inc. 	3,219	$ 	3,002	$ 	2,941	$ 	9,161	$ 	2,915	$ 	2,670	$ 	1,901	$ 	7,487	$ 	2,357	$ 	9,843	$ 	55% 	22%
Earnings per Common Share Assuming Dilution 	1.26	$ 	1.18	$ 	1.16	$ 	3.61	$ 	1.12	$ 	1.03	$ 	0.74	$ 	2.89	$ 	0.92	$ 	3.81	$ 	57% 	25%
Average Shares Outstanding Assuming Dilution 	2,547 	2,536 	2,538 	2,541 	2,603 	2,588 	2,572 	2,587 	2,559 	2,580
Tax Rate 	16.1% 	14.5% 	14.1% 	14.9% 	6.7% 	18.9% 	18.7% 	14.5% 	15.3% 	14.7%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
Sep YTD	2Q 	3Q 	Sep YTD 	4Q 	Full Year 	3Q	1Q 	2Q 	3Q 	Sep YTD 	1Q
2020 	2019 	% Change
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1a
2	2

-- 3 of 12 --

Cost of sales 	3,481	$ 	285 	38 	323 	3,158	$
Selling, general and administrative 	2,450 	207 	15 	222 	2,228
Research and development 	3,390 	16 	19 	1,082 	1,117 	2,273
Restructuring costs 	114 	114 	114 	-
Other (income) expense, net 	(312) 	(1) 	(1) 	(311)
Income Before Taxes 	3,428 	(508) 	(186) 	(1,081) 	(1,775) 	5,203
Income Tax Provision (Benefit) 	483 	(17) (3) (25) (3) (247) (3) (289) 	772
Net Income 	2,945 	(491) 	(161) 	(834) 	(1,486) 	4,431
Net Income Attributable to Merck & Co., Inc. 	2,941 	(491) 	(161) 	(834) 	(1,486) 	4,427
Earnings per Common Share Assuming Dilution 	1.16	$ 	(0.19) 	(0.06) 	(0.33) 	(0.58) 	1.74	$
Tax Rate 	14.1% 	14.8%
Only the line items that are affected by non-GAAP adjustments are shown.
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance
and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP.
(1) Amount included in cost of sales primarily reflects expenses for the amortization of intangible assets recognized as a result of business acquisitions. Amount included in selling, general and
administrative expenses reflects $182 million related to the company's planned spin-off of Organon & Co., and other acquisition and divestiture-related costs.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal
restructuring programs.
(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Acquisition and divestiture-related
costs also includes a tax cost of $67 million, representing an adjustment to the tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition.
(4) Amount included in research and development reflects expenses for upfront payments related to license and collaboration agreements.
Non-GAAP
MERCK & CO., INC.
GAAP TO NON-GAAP RECONCILIATION
THIRD QUARTER 2020
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a
GAAP
Acquisition and
Divestiture-Related
Costs (1)
Restructuring
Costs (2)
Certain Other
Items (4)
Adjustment
Subtotal
3	3

-- 4 of 12 --

Cost of sales 	9,952	$ 	863 	131 	994 	8,958	$
Selling, general and administrative 	7,383 	648 	37 	685 	6,698
Research and development 	7,721 	(12) 	67 	1,082 	1,137 	6,584
Restructuring costs 	269 	269 	269 	-
Other (income) expense, net 	(630) 	52 	(17) 	35 	(665)
Income Before Taxes 	10,784 	(1,551) 	(504) 	(1,065) 	(3,120) 	13,904
Income Tax Provision (Benefit) 	1,611 	(248) (3) (59) (3) (242) (3) (549) 	2,160
Net Income 	9,173 	(1,303) 	(445) 	(823) 	(2,571) 	11,744
Net Income Attributable to Merck & Co., Inc. 	9,161 	(1,303) 	(445) 	(823) 	(2,571) 	11,732
Earnings per Common Share Assuming Dilution 	3.61	$ 	(0.51) 	(0.18) 	(0.32) 	(1.01) 	4.62	$
Tax Rate 	14.9% 	15.5%
Only the line items that are affected by non-GAAP adjustments are shown.
GAAP
Acquisition and
Divestiture-Related
Costs (1)
Restructuring
Costs (2)
Certain Other
Items (4)
Adjustment
Subtotal Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance
and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP.
(1) Amount included in cost of sales primarily reflects expenses for the amortization of intangible assets recognized as a result of business acquisitions. Amount included in selling, general and
administrative expenses reflects $466 million related to the company's planned spin-off of Organon & Co., approximately $95 million of costs related to the acquisition of ArQule, Inc., and other
acquisition and divestiture-related costs. Amount included in research and development expenses primarily reflects a reduction in expenses related to a decrease in the estimated fair value
measurement of liabilities for contingent consideration. Amount included in other (income) expense, net, primarily reflects an increase in the estimated fair value measurement of liabilities for
contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture, partially offset by royalty income.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal
restructuring programs.
(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Acquisition and divestiture-related
costs also includes a tax cost of $67 million, representing an adjustment to the tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition.
(4) Amount included in research and development reflects expenses for upfront payments related to license and collaboration agreements.
Table 2b
MERCK & CO., INC.
GAAP TO NON-GAAP RECONCILIATION
NINE MONTHS ENDED SEPTEMBER 30, 2020
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
4	4

-- 5 of 12 --

Cost of sales 	3,990	$ 	941 	62 	1,003 	2,987	$
Selling, general and administrative 	2,589 	22 	1 	23 	2,566
Research and development 	3,204 	6 	1 	982 	989 	2,215
Restructuring costs 	232 	232 	232 	-
Other (income) expense, net 	35 	6 	6 	29
Income Before Taxes 	2,347 	(975) 	(296) 	(982) 	(2,253) 	4,600
Income Tax Provision (Benefit) 	440 	(231) (3) (50) (3) - 	(281) 	721
Net Income 	1,907 	(744) 	(246) 	(982) 	(1,972) 	3,879
Net Income Attributable to Merck & Co., Inc. 	1,901 	(744) 	(246) 	(982) 	(1,972) 	3,873
Earnings per Common Share Assuming Dilution 	0.74	$ 	(0.29) 	(0.10) 	(0.38) 	(0.77) 	1.51	$
Tax Rate 	18.7% 	15.7%
Only the line items that are affected by non-GAAP adjustments are shown.
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance
and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP.
(1) Amount included in cost of sales primarily reflects $320 million of expenses for the amortization of intangible assets recognized as a result of business acquisitions, as well as $612 million of
intangible asset impairment charges related to SIVEXTRO. Amount included in selling, general and administrative expenses primarily reflects integration, transaction and certain other costs
related to business acquisitions and divestitures.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal
restructuring programs.
(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
(4) Amount included in research and development represents the charge related to the acquisition of Peloton Therapeutics, Inc.
Non-GAAP
MERCK & CO., INC.
GAAP TO NON-GAAP RECONCILIATION
THIRD QUARTER 2019
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2c
GAAP
Acquisition and
Divestiture-Related
Costs (1)
Restructuring
Costs (2)
Certain Other
Items (4)
Adjustment
Subtotal
5	5

-- 6 of 12 --

Cost of sales 	10,443	$ 	1,801 	161 	1,962 	8,481	$
Selling, general and administrative 	7,726 	82 	33 	115 	7,611
Research and development 	7,324 	(21) 	4 	982 	965 	6,359
Restructuring costs 	444 	444 	444 	-
Other (income) expense, net 	362 	321 	48 	369 	(7)
Income Before Taxes 	8,673 	(2,183) 	(642) 	(1,030) 	(3,855) 	12,528
Income Tax Provision (Benefit) 	1,259 	(438) (3) (106) (3) (304) (5) (848) 	2,107
Net Income 	7,414 	(1,745) 	(536) 	(726) 	(3,007) 	10,421
Less: Net (Loss) Income Attributable to
Noncontrolling Interests (73) 	(89) 	(89) 	16
Net Income Attributable to Merck & Co., Inc. 	7,487 	(1,656) 	(536) 	(726) 	(2,918) 	10,405
Earnings per Common Share Assuming Dilution 	2.89	$ 	(0.64) 	(0.21) 	(0.28) 	(1.13) 	4.02	$
Tax Rate 	14.5% 	16.8%
Only the line items that are affected by non-GAAP adjustments are shown.
(5) Primarily reflects a $360 million net tax benefit related to the settlement of certain federal income tax matters and a $67 million tax charge related to the finalization of treasury regulations
associated with the 2017 enactment of U.S. tax legislation.
GAAP
Acquisition and
Divestiture-Related
Costs (1)
Restructuring
Costs (2)
Certain Other
Items (4)
Adjustment
Subtotal Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance
and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP.
(1) Amount included in cost of sales primarily reflects $1.1 billion of expenses for the amortization of intangible assets recognized as a result of business acquisitions, as well as $693 million of
intangible asset impairment charges, including $612 million related to SIVEXTRO. Amount included in selling, general and administrative expenses primarily reflects integration, transaction and
certain other costs related to business acquisitions and divestitures, including costs related to the acquisition of Antelliq Corporation. Amount included in research and development expenses
primarily reflects a reduction in expenses related to a decrease in the estimated fair value measurement of liabilities for contingent consideration. Amount included in other (income) expense,
net primarily reflects goodwill and intangible asset impairment charges related to certain businesses in the Healthcare Services segment and expenses related to an increase in the estimated
fair value measurement of liabilities for contingent consideration, partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal
restructuring programs.
(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
(4) Amount included in research and development represents the charge related to the acquisition of Peloton Therapeutics, Inc.
Table 2d
MERCK & CO., INC.
GAAP TO NON-GAAP RECONCILIATION
NINE MONTHS ENDED SEPTEMBER 30, 2019
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
6	6

-- 7 of 12 --

1Q 	2Q 	3Q 	Sep YTD 	1Q 	2Q 	3Q 	Sep YTD 	4Q 	Full Year 	Nom % 	Ex-Exch % 	Nom % 	Ex-Exch %
TOTAL SALES (1) $12,057 	$10,872 	$12,551 	$35,479 	$10,816 	$11,760 	$12,397 	$34,972 	$11,868 	$46,840 	1 	2 	1 	3
PHARMACEUTICAL 	10,655 	9,679 	11,320 	31,654 	9,663 	10,460 	11,095 	31,218 	10,533 	41,751 	2 	2 	1 	3
Oncology
Keytruda 	3,284 	3,388 	3,715 	10,387 	2,269 	2,634 	3,070 	7,973 	3,111 	11,084 	21 	21 	30 	31
Alliance Revenue – Lynparza (2) 145 	178 	196 	519 	79 	111 	123 	313 	132 	444 	59 	58 	66 	67
Alliance Revenue – Lenvima (2) 128 	151 	142 	421 	74 	97 	109 	280 	124 	404 	30 	29 	50 	50
Emend 	43 	33 	39 	115 	117 	121 	98 	336 	53 	388 	-60 	-59 	-66 	-65
Vaccines (3)
Gardasil / Gardasil 9 	1,097 	656 	1,187 	2,941 	838 	886 	1,320 	3,044 	693 	3,737 	-10 	-10 	-3 	-2
ProQuad / M-M-R II / Varivax 	435 	378 	576 	1,390 	496 	675 	623 	1,794 	481 	2,275 	-8 	-7 	-23 	-22
Pneumovax 23 	256 	117 	375 	748 	185 	170 	237 	592 	334 	926 	58 	58 	26 	27
RotaTeq 	222 	168 	210 	601 	211 	172 	180 	564 	227 	791 	16 	17 	7 	8
Vaqta 	60 	28 	51 	139 	47 	58 	62 	167 	71 	238 	-18 	-17 	-17 	-15
Hospital Acute Care
Bridion 	299 	224 	320 	843 	255 	278 	284 	817 	313 	1,131 	13 	13 	3 	4
Noxafil 	94 	73 	79 	247 	190 	193 	177 	560 	103 	662 	-55 	-55 	-56 	-55
Prevymis 	60 	63 	77 	200 	32 	38 	45 	115 	50 	165 	72 	69 	74 	74
Primaxin 	51 	64 	74 	189 	59 	71 	77 	207 	67 	273 	-4 	-4 	-9 	-7
Invanz 	64 	43 	51 	159 	72 	78 	57 	206 	57 	263 	-10 	-6 	-23 	-19
Cancidas 	55 	43 	50 	148 	61 	67 	62 	191 	58 	249 	-20 	-19 	-22 	-20
Cubicin 	46 	32 	39 	116 	88 	67 	52 	207 	50 	257 	-26 	-25 	-44 	-43
Zerbaxa 	37 	32 	43 	112 	26 	27 	35 	88 	32 	121 	22 	24 	27 	29
Immunology
Simponi 	215 	191 	209 	615 	208 	214 	203 	625 	205 	830 	3 	-2 	-1
Remicade 	88 	73 	82 	242 	123 	98 	101 	322 	89 	411 	-19 	-20 	-25 	-24
Neuroscience
Belsomra 	79 	84 	81 	244 	67 	76 	80 	223 	83 	306 	1 	9 	8
Virology
Isentress / Isentress HD 	245 	196 	205 	646 	255 	247 	250 	752 	223 	975 	-18 	-18 	-14 	-12
Zepatier 	55 	39 	28 	122 	114 	108 	83 	304 	66 	370 	-67 	-67 	-60 	-59
Cardiovascular
Zetia 	145 	137 	103 	384 	140 	156 	147 	443 	146 	590 	-30 	-30 	-13 	-13
Vytorin 	53 	39 	47 	139 	97 	76 	57 	231 	54 	285 	-17 	-16 	-40 	-38
Atozet 	122 	115 	111 	348 	94 	92 	97 	283 	108 	391 	14 	12 	23 	25
Alliance Revenue - Adempas (4) 53 	79 	83 	216 	42 	51 	50 	144 	60 	204 	67 	67 	50 	50
Adempas (5) 56 	57 	55 	167 	48 	53 	57 	158 	57 	215 	-5 	-7 	6 	6
Diabetes (6)
Januvia 	774 	854 	821 	2,449 	824 	908 	807 	2,539 	943 	3,482 	2 	2 	-4 	-3
Janumet 	503 	490 	506 	1,499 	530 	533 	503 	1,567 	475 	2,041 	2 	-4 	-2
Women's Health
Implanon / Nexplanon 	195 	132 	189 	515 	199 	183 	199 	581 	206 	787 	-5 	-4 	-11 	-10
NuvaRing 	63 	63 	58 	184 	219 	240 	241 	700 	179 	879 	-76 	-76 	-74 	-73
Diversified Brands
Singulair 	155 	100 	82 	338 	191 	160 	152 	503 	195 	698 	-46 	-46 	-33 	-32
Cozaar / Hyzaar 	102 	98 	91 	292 	103 	109 	116 	329 	113 	442 	-21 	-20 	-11 	-9
Arcoxia 	70 	65 	68 	204 	75 	75 	72 	221 	67 	288 	-5 	-2 	-8 	-5
Nasonex 	71 	49 	41 	161 	96 	72 	58 	226 	67 	293 	-30 	-29 	-29 	-27
Follistim AQ 	41 	44 	50 	136 	57 	63 	62 	182 	58 	241 	-18 	-18 	-26 	-25
Other Pharmaceutical (7) 1,194 	1,103 	1,186 	3,478 	1,082 	1,203 	1,149 	3,431 	1,183 	4,615 	3 	4 	1 	3
ANIMAL HEALTH 	1,214 	1,101 	1,220 	3,535 	1,025 	1,124 	1,122 	3,271 	1,122 	4,393 	9 	12 	8 	12
Livestock 	739 	648 	758 	2,145 	611 	671 	726 	2,007 	777 	2,784 	5 	8 	7 	11
Companion Animals 	475 	453 	462 	1,390 	414 	453 	396 	1,264 	345 	1,609 	17 	18 	10 	12
Other Revenues (8) 188 	92 	11 	290 	128 	176 	180 	483 	213 	696 	-94 	-33 	-40 	-12
(6) Total Diabetes sales were $1,353 million, $1,418 million and $1,405 million in the first, second and third quarters of 2020 and $1,402 million, $1,480 million, $1,360 million and $1,472 million in the
first, second, third and fourth quarters of 2019, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of Healthcare Services segment revenues, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Total Vaccines sales were $2,155 million, $1,418 million and $2,521 million in the first, second and third quarters of 2020 and $1,887 million, $2,037 million, $2,517 million and $1,928 million in the
first, second, third and fourth quarters of 2019, respectively.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
2020 	2019 	3Q 	Sep YTD
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
7	7

-- 8 of 12 --

3Q 2020 	3Q 2019 	% Change 	3Q 2020 	3Q 2019 	% Change 	3Q 2020 	3Q 2019 	% Change
TOTAL SALES (1) $12,551 	$12,397 	1 	$5,625 	$5,573 	1 	$6,926 	$6,824 	1
PHARMACEUTICAL 	11,320 	11,095 	2 	5,218 	5,180 	1 	6,102 	5,914 	3
Oncology
Keytruda 	3,715 	3,070 	21 	2,157 	1,743 	24 	1,559 	1,327 	17
Alliance Revenue - Lynparza (2) 196 	123 	59 	107 	71 	52 	89 	53 	70
Alliance Revenue - Lenvima (2) 142 	109 	30 	82 	65 	26 	60 	44 	36
Emend 	39 	98 	-60 	8 	42 	-82 	31 	56 	-44
Vaccines (3)
Gardasil / Gardasil 9 	1,187 	1,320 	-10 	579 	761 	-24 	608 	558 	9
ProQuad / M-M-R II / Varivax 	576 	623 	-8 	437 	482 	-9 	139 	141 	-2
Pneumovax 23 	375 	237 	58 	276 	179 	54 	99 	58 	72
RotaTeq 	210 	180 	16 	114 	102 	11 	96 	78 	23
Vaqta 	51 	62 	-18 	32 	36 	-11 	19 	26 	-26
Hospital Acute Care
Bridion 	320 	284 	13 	162 	133 	22 	157 	151 	4
Noxafil 	79 	177 	-55 	13 	77 	-83 	66 	100 	-34
Prevymis 	77 	45 	72 	32 	22 	42 	46 	23 	101
Primaxin 	74 	77 	-4 	1 	2 	-34 	73 	75 	-3
Invanz 	51 	57 	-10 	1 	(1) 	* 	50 	58 	-14
Cancidas 	50 	62 	-20 	1 	0 	80 	49 	62 	-21
Zerbaxa 	43 	35 	22 	20 	20 	4 	23 	15 	47
Cubicin 	39 	52 	-26 	11 	14 	-22 	28 	38 	-28
Immunology
Simponi 	209 	203 	3 	209 	203 	3
Remicade 	82 	101 	-19 	82 	101 	-19
Neuroscience
Belsomra 	81 	80 	1 	18 	23 	-24 	63 	57 	11
Virology
Isentress / Isentress HD 	205 	250 	-18 	92 	102 	-10 	113 	149 	-24
Zepatier 	28 	83 	-67 	6 	24 	-76 	22 	59 	-63
Cardiovascular
Zetia 	103 	147 	-30 	(1) 	5 	-115 	103 	142 	-27
Vytorin 	47 	57 	-17 	3 	5 	-34 	44 	52 	-16
Atozet 	111 	97 	14 	111 	97 	14
Alliance Revenue - Adempas (4) 83 	50 	67 	78 	48 	64 	5 	2 	117
Adempas (5) 55 	57 	-5 	55 	57 	-5
Diabetes (6)
Januvia 	821 	807 	2 	342 	367 	-7 	479 	440 	9
Janumet 	506 	503 	105 	129 	-18 	400 	375 	7
Women's Health
Implanon / Nexplanon 	189 	199 	-5 	137 	136 	1 	52 	62 	-17
NuvaRing 	58 	241 	-76 	24 	202 	-88 	34 	39 	-13
Diversified Brands
Cozaar / Hyzaar 	91 	116 	-21 	5 	6 	-7 	86 	110 	-22
Singulair 	82 	152 	-46 	4 	11 	-61 	78 	140 	-44
Arcoxia 	68 	72 	-5 	68 	72 	-5
Follistim AQ 	50 	62 	-18 	20 	27 	-28 	31 	35 	-11
Nasonex 	41 	58 	-30 	4 	-110 	41 	55 	-24
Other Pharmaceutical (7) 1,186 	1,149 	3 	352 	343 	3 	834 	804 	4
ANIMAL HEALTH 	1,220 	1,122 	9 	398 	337 	18 	822 	785 	5
Livestock 	758 	726 	5 	164 	144 	14 	594 	582 	2
Companion Animals 	462 	396 	17 	234 	193 	22 	228 	203 	12
Other Revenues (8) 11 	180 	-94 	9 	56 	-85 	2 	125 	-99
* 200% or greater
Sum of U.S. plus international may not equal global due to rounding.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
(6) Total Diabetes sales were $1,405 million and $1,360 million on a global basis in the third quarter of 2020 and 2019, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of Healthcare Services segment revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.
(3) Total Vaccines sales were $2,521 million and $2,517 million on a global basis in the third quarter of 2020 and 2019, respectively.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
THIRD QUARTER 2020
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
8	8

-- 9 of 12 --

Sep YTD 2020 Sep YTD 2019 	% Change 	Sep YTD 2020 Sep YTD 2019 	% Change 	Sep YTD 2020 Sep YTD 2019 	% Change
TOTAL SALES (1) $35,479 	$34,972 	1 	$15,396 	$15,320 	$20,084 	$19,652 	2
PHARMACEUTICAL 	31,654 	31,218 	1 	14,202 	14,202 	17,452 	17,016 	3
Oncology
Keytruda 	10,387 	7,973 	30 	6,106 	4,525 	35 	4,281 	3,448 	24
Alliance Revenue - Lynparza (2) 519 	313 	66 	297 	186 	59 	223 	126 	76
Alliance Revenue - Lenvima (2) 421 	280 	50 	270 	169 	60 	152 	112 	36
Emend 	115 	336 	-66 	18 	173 	-89 	96 	163 	-41
Vaccines (3)
Gardasil / Gardasil 9 	2,941 	3,044 	-3 	1,209 	1,579 	-23 	1,732 	1,464 	18
ProQuad / M-M-R II / Varivax 	1,390 	1,794 	-23 	1,033 	1,325 	-22 	356 	469 	-24
Pneumovax 23 	748 	592 	26 	478 	428 	12 	270 	164 	64
RotaTeq 	601 	564 	7 	355 	360 	-2 	246 	203 	21
Vaqta 	139 	167 	-17 	79 	103 	-23 	60 	65 	-7
Hospital Acute Care
Bridion 	843 	817 	3 	412 	381 	8 	431 	437 	-1
Noxafil 	247 	560 	-56 	27 	268 	-90 	220 	291 	-25
Prevymis 	200 	115 	74 	87 	60 	45 	113 	55 	106
Primaxin 	189 	207 	-9 	2 	2 	187 	204 	-9
Invanz 	159 	206 	-23 	7 	30 	-77 	152 	176 	-14
Cancidas 	148 	191 	-22 	2 	5 	-63 	147 	187 	-21
Cubicin 	116 	207 	-44 	36 	78 	-54 	80 	129 	-37
Zerbaxa 	112 	88 	27 	57 	45 	27 	54 	43 	26
Immunology
Simponi 	615 	625 	-2 	615 	625 	-2
Remicade 	242 	322 	-25 	242 	322 	-25
Neuroscience
Belsomra 	244 	223 	9 	67 	68 	-2 	177 	155 	14
Virology
Isentress / Isentress HD 	646 	752 	-14 	243 	304 	-20 	403 	449 	-10
Zepatier 	122 	304 	-60 	38 	96 	-60 	83 	208 	-60
Cardiovascular
Zetia 	384 	443 	-13 	(4) 	11 	-140 	389 	432 	-10
Vytorin 	139 	231 	-40 	9 	11 	-23 	130 	219 	-41
Atozet 	348 	283 	23 	348 	283 	23
Alliance Revenue - Adempas (4) 216 	144 	50 	200 	137 	46 	16 	7 	130
Adempas (5) 167 	158 	6 	167 	158 	6
Diabetes (6)
Januvia 	2,449 	2,539 	-4 	1,110 	1,223 	-9 	1,339 	1,317 	2
Janumet 	1,499 	1,567 	-4 	361 	462 	-22 	1,138 	1,105 	3
Women's Health
Implanon / Nexplanon 	515 	581 	-11 	374 	421 	-11 	142 	160 	-12
NuvaRing 	184 	700 	-74 	85 	593 	-86 	98 	107 	-8
Diversified Brands
Singulair 	338 	503 	-33 	14 	24 	-44 	324 	479 	-32
Cozaar / Hyzaar 	292 	329 	-11 	17 	16 	6 	275 	313 	-12
Arcoxia 	204 	221 	-8 	204 	221 	-8
Nasonex 	161 	226 	-29 	9 	2 	* 	152 	224 	-32
Follistim AQ 	136 	182 	-26 	60 	80 	-26 	76 	102 	-26
Other Pharmaceutical (7) 3,478 	3,431 	1 	1,144 	1,037 	10 	2,334 	2,394 	-3
ANIMAL HEALTH 	3,535 	3,271 	8 	1,124 	966 	16 	2,411 	2,305 	5
Livestock 	2,145 	2,007 	7 	448 	406 	10 	1,697 	1,601 	6
Companion Animals 	1,390 	1,264 	10 	676 	560 	21 	714 	704 	2
Other Revenues (8) 290 	483 	-40 	70 	152 	-54 	221 	331 	-33
* 200% or greater
Sum of U.S. plus international may not equal global due to rounding.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
(6) Total Diabetes sales were $4,177 million and $4,242 million on a global basis for September YTD 2020 and 2019, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of Healthcare Services segment revenues, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.
(3) Total Vaccines sales were $6,094 million and $6,441 million on a global basis for September YTD 2020 and 2019, respectively.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
SEPTEMBER YEAR-TO-DATE 2020
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
9	9

-- 10 of 12 --

% Change
TOTAL PHARMACEUTICAL 	$10,655 	$9,679 	$11,320 	$31,654 	$9,663 	$10,460 	$11,095 	$31,218 	$10,533 	$41,751 	2
United States (1) 4,714 	4,270 	5,218 	14,202 	4,215 	4,807 	5,180 	14,202 	4,751 	18,953 	1
% Pharmaceutical Sales 	44.2% 	44.1% 	46.1% 	44.9% 	43.6% 	46.0% 	46.7% 	45.5% 	45.1% 	45.4%
Europe (2) 2,543 	2,196 	2,549 	7,288 	2,335 	2,301 	2,304 	6,941 	2,373 	9,314 	11
% Pharmaceutical Sales 	23.9% 	22.7% 	22.5% 	23.0% 	24.2% 	22.0% 	20.8% 	22.2% 	22.5% 	22.3%
China 	846 	811 	990 	2,646 	725 	745 	898 	2,368 	773 	3,141 	10
% Pharmaceutical Sales 	7.9% 	8.4% 	8.7% 	8.4% 	7.5% 	7.1% 	8.1% 	7.6% 	7.3% 	7.5%
Japan 	789 	847 	805 	2,441 	779 	900 	894 	2,573 	921 	3,494 	-10
% Pharmaceutical Sales 	7.4% 	8.8% 	7.1% 	7.7% 	8.1% 	8.6% 	8.1% 	8.2% 	8.7% 	8.4%
Asia Pacific (other than China and Japan) 	613 	555 	601 	1,769 	642 	606 	638 	1,886 	614 	2,500 	-6
% Pharmaceutical Sales 	5.8% 	5.7% 	5.3% 	5.6% 	6.6% 	5.8% 	5.8% 	6.0% 	5.8% 	6.0%
Eastern Europe/Middle East/Africa 	490 	416 	419 	1,325 	343 	388 	423 	1,154 	423 	1,577 	-1
% Pharmaceutical Sales 	4.6% 	4.3% 	3.7% 	4.2% 	3.6% 	3.7% 	3.8% 	3.7% 	4.0% 	3.8%
Latin America 	419 	399 	477 	1,294 	427 	523 	534 	1,484 	429 	1,914 	-11
% Pharmaceutical Sales 	3.9% 	4.1% 	4.2% 	4.1% 	4.4% 	5.0% 	4.8% 	4.8% 	4.1% 	4.6%
Canada 	212 	160 	216 	589 	177 	179 	211 	568 	216 	783 	2
% Pharmaceutical Sales 	2.0% 	1.7% 	1.9% 	1.9% 	1.8% 	1.7% 	1.9% 	1.8% 	2.0% 	1.9%
Other (1) 29 	25 	45 	100 	20 	11 	13 	42 	33 	75 	246
% Pharmaceutical Sales 	0.3% 	0.3% 	0.4% 	0.3% 	0.2% 	0.1% 	0.1% 	0.1% 	0.3% 	0.2%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Alliance revenue related to Adempas attributable to the United States has been reclassified from Other.
(2) Europe primarily represents all European Union countries and the European Union accession markets.
3Q 	Sep YTD 	4Q 	Full Year 	3Q	1Q 	2Q 	3Q 	Sep YTD 	1Q 	2Q
2020 	2019
MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
10	10

-- 11 of 12 --

OTHER (INCOME) EXPENSE, NET
3Q20 	3Q19 	Sep YTD 2020 Sep YTD 2019
Interest income 	(9)	$ 	(61)	$ 	(48)	$ 	(225)	$
Interest expense 	203 	231 	624 	674
Exchange losses 	10 	38 	89 	166
Income from investments in equity securities, net (1) (360) 	(16) 	(964) 	(50)
Net periodic defined benefit plan (credit) cost other than service cost 	(88) 	(128) 	(259) 	(409)
Other, net 	(68) 	(29) 	(72) 	206
Total 	(312)	$ 	35	$ 	(630)	$ 	362	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are
accounted for on a one quarter lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
11	11

-- 12 of 12 --